Metabolic profile of a peptide-conjugated chlorin-type photosensitizer targeting neuropilin-1: An in vivo and in vitro study

Drug Metabolism and Disposition

Volumn 35, Issue 5, 2007, Pages 806-813

  Tirand, Loraine ^a   Thomas, Noémie ^a   Dodeller, Marc ^c   Dumas, Dominique ^b   Frochot, Céline ^d   Maunit, Benoît ^c   Guillemin, François ^a   Barberi Heyob, Muriel ^a,e  

^a CENTRE DE RECHERCHE EN AUTOMATIQUE DE NANCY   (France)

^b NANCY UNIVERSITÉ   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d UNIVERSITÉ DE LORRAINE   (France)

^e CENTRE ALEXIS VAUTRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CARBOXYPHENYL) 10,15,20 TRIPHENYLCHLORIN; ENDOTHELIAL CELL GROWTH FACTOR; NEUROPILIN 1; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO CULTURE; LYSOSOME; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TUMOR VASCULARIZATION; UMBILICAL VEIN;

6-AMINOCAPROIC ACID; AMMONIUM CHLORIDE; ANIMALS; CELL LINE; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENDOPLASMIC RETICULUM; ENDOTHELIAL CELLS; FEMALE; GLIOMA; GOLGI APPARATUS; HUMANS; INJECTIONS, INTRAVENOUS; LYSOSOMES; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; MOLECULAR STRUCTURE; NEUROPILIN-1; OLIGOPEPTIDES; PHOTOSENSITIZING AGENTS; PORPHYRINS; SKIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 34247336893     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.013763     Document Type: Article

References (25)

1. Adessi C and Soto C (2002) Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr Med Chem 9:963-978.
2. Barberi-Heyob M, Vedrine PO, Merlin JL, Millon R, Abecassis J, Poupon MF, and Guillemin F (2004) Wild-type p53 gene transfer into mutated p53 HT29 cells improves sensitivity to photodynamic therapy via induction of apoptosis. Int J Oncol 24:951-958.
3. Cramers P, Ruevekamp M, Oppelaar H, Dalesio O, Baas P, and Stewart FA (2003) Foscam uptake and tissue distribution in relation to photodynamic efficacy. Br J Cancer 88:283-290.
4. Di Stasio B, Frochot C, Dumas D, Even P, Zwier J, Muller A, Didelon J, Guillemin F, Viriot ML, and Barberi-Heyob M (2005) The 2-aminoglucosamide motif improves cellular uptake and photodynamic activity of tetraphenylporphyrin. Eur J Med Chem 40:1111-1122.
5. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, and Peng Q (1998) Photodynamic therapy. J Natl Cancer Inst 90:889-905.
6. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31.
7. Hopkinson HJ, Vernon DI, and Brown SB (1999) Identification and partial characterization of an unusual distribution of the photosensitizer meta-tetrahydroxyphenyl chlorin (temoporfin) in human plasma. Photochem Photobiol 69:482-488.
8. Ichikawa K, Hikita T, Maeda N, Yonezawa S, Takeuchi Y, Asai T, Namba Y, and Oku N (2005) Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels. Biochim Biophys Acta 1669:69-74.
9. Janssen AP, Schiffelers RM, ten Hagen TL, Koning GA, Schraa AJ, Kok RJ, Storm G, and Molema G (2003) Peptide-targeted PEG-liposomes in anti-angiogenic therapy. Int J Pharm 254:55-58.
10. Jones HJ, Vernon DI, and Brown SB (2003) Photodynamic therapy effect of m-THPC (Foscan) in vivo: correlation with pharmacokinetics. Br J Cancer 89:398-404.
11. Jori G and Fabris C (1998) Relative contributions of apoptosis and random necrosis in tumour response to photodynamic therapy: effect of the chemical structure of Zn(II)-phthalocyanines. J Photochem Photobiol B 43:181-185.
12. Laville I, Pigaglio S, Blais JC, Loock B, Maillard P, Grierson DS, and Blais J (2004) A study of the stability of tri(glucosyloxyphenyl)chlorin, a sensitizer for photodynamic therapy, in human colon tumoural cells: a liquid chromatography and MALDI-TOF mass spectrometry analysis. Bioorg Med Chem 12:3673-3682.
13. McDonald JK and Barrette AJ (1980) Mammalian Proteases: A Glossary and Bibliography. 1. Endopeptidases, Academic Press, London.
14. McDonald JK and Barrette AJ (1986) Mammalian Proteases: A Glossary and Bibliography. 2. Exopeptidases, Academic Press, London.
15. Perret GY, Starzec A, Hauet N, Vergote J, Le Pecheur M, Vassy R, Leger G, Verbeke KA, Bormans G, Nicolas P, et al. (2004) In vitro evaluation and biodistribution of a 99mTc-labeled anti-VEGF peptide targeting neuropilin-1. Nucl Med Biol 31:575-581.
16. Powell MF, Stewart T, Otvos L Jr, Urge L, Gaeta FC, Sette A, Arrhenius T, Thomson D, Soda K, and Colon SM (1993) Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum. Pharm Res (NY) 10:1268-1273.
17. Renno RZ, Terada Y, Haddadin MJ, Michaud NA, Gragoudas ES, and Miller JW (2004) Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Arch Ophthalmol 122:1002-1011.
18. Roberts R (2005) Lysosomal cysteine proteases: structure, function and inhibition of cathepsins. Drug News Perspect 18:605-614.
19. Rodrigues S, Van Aken E, Van Bocxlaer S, Attoub S, Nguyen QD, Bruyneel E, Westley BR, May FE, Thim L, Mareel M, et al. (2003) Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling. FASEB J 17:7-16.
20. Rosenkranz AA, Jans DA, and Sobolev AS (2000) Targeted intracellular delivery of photosensitizers to enhance photodynamic efficiency. Immunol Cell Biol 78:452-464.
21. Schmidt U, Birngruber R, and Hasan T (1992) [Selective occlusion of ocular neovascularization by photodynamic therapy]. Ophthalmologe 89:391-394.
22. Schneider R, Tirand L, Frochot C, Vanderesse R, Thomas N, Gravier J, Guillemin F, and Barberi-Heyob M (2006) Recent improvements in the use of synthetic peptides for a selective photodynamic therapy. Anticancer Agents Med Chem 6:469-488.
23. Sharman WM, van Lier JE, and Allen CM (2004) Targeted photodynamic therapy via receptor mediated delivery systems. Adv Drug Deliv Rev 56:53-76.
24. Tirand L, Frochot C, Vanderesse R, Thomas N, Trinquet E, Pinel S, Viriot ML, Guillemin F, and Barberi-Heyob M (2006) A peptide competing with VEGF(165) binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells. J Controlled Release 111:153-164.
25. Tournaire R, Demangel C, Derbin C, Perret G, Mazie J-C, Plouet J, and Vassy R (2001) Peptides blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis polynucleotides encoding said peptides and methods of use thereof. International Patent Application Publication No. WO-01/72829.